Trailing Twelve Months Sales Growth: Pieris Corp (PVLA)

Pieris Pharmaceuticals (PVLA) management focuses on creating unique anticalin proteins to combat oncology. Analyzing the chart on GURU.Markets, we find that the TTM revenue growth rate compared to the same period last year exhibits volatility, where 0.00 indicates the current level. The strategy relies on partnerships with industry behemoths, although a deep portfolio restructuring necessitates the search for new clinical targets.
Pieris Pharma (PVLA) - metric breakdowns and financial figures

This indicator neutralizes quarterly volatility by calculating revenue dynamics over a rolling year to identify the true trajectory of business development. Analyzing year-over-year revenue changes over a 12-month TTM period allows for an assessment of the cash flow stability of Pieris Pharmaceuticals (PVLA) during a period of molecule portfolio restructuring and limited funding for new R&D projects.